A recent study published at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition suggests that GLP-1 receptor agonists (GLP-1 RAs) like semaglutide could significantly reduce stroke risk in individuals with type 2 diabetes.

This retrospective, propensity score-matched multicenter database analysis compared the effects of GLP-1 RAs with DPP-4 inhibitors, another type of antihyperglycemic medication. The analysis revealed a striking 18% reduction in the risk of venous thromboembolism (VTE) among patients using GLP-1 RAs.

Study Details

Led by Rushad Patell, MD, an assistant professor of medicine at Harvard Medical School, the study included over 650,000 patients. Exclusion criteria included a history of oral anticoagulation, prior VTE, or atrial fibrillation.

Using data from the TriNetX Analytics Network, researchers meticulously matched patients based on key clinical variables, such as age, sex, race, BMI, hemoglobin A1c, and other relevant medical conditions. The primary outcome measured was the incidence rate of VTE per 1,000 patient-years after starting GLP-1 RA or DPP-4 inhibitors.

Key Findings

• Patients using GLP-1 RAs experienced a lower incidence of VTE (11.0 events per 1,000 patient-years) compared to those using DPP-4 inhibitors (12.9 events per 1,000 patient-years).
• A significant reduction in both pulmonary embolism and deep vein thrombosis was observed in the GLP-1 RA group.

Implications for Healthcare Professionals

"Our study showed that the use of a GLP-1 receptor agonist is associated with lower incidence of VTE over one year," said Dr. Patell. "If you’re selecting an antidiabetic agent for a patient and thrombotic risk comes into play, this data suggests that there may be some advantage to choosing a GLP-1 receptor agonist."

Dr. Patell further highlights the potential public health impact: "From a public health perspective, given how prevalent these drugs are, there is potential to see if the overall burden of VTE might be reduced at a national or population level."

Stay Informed

This research further solidifies the growing body of evidence supporting the multifaceted benefits of GLP-1 RAs in managing type 2 diabetes.

For the most up-to-date information on medications and treatments for type 2 diabetes, consult with your healthcare provider.